204 related articles for article (PubMed ID: 11169927)
1. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
2. Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Nair JS; Kancherla R; Seiter K; Traganos F; Tse-Dinh YC
Ann N Y Acad Sci; 2000; 922():326-9. PubMed ID: 11193914
[No Abstract] [Full Text] [Related]
3. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
[TBL] [Abstract][Full Text] [Related]
4. Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Mainwaring MG; Rimsza LM; Chen SF; Gomez SP; Weeks FW; Reddy V; Lynch J; May WS; Kahn S; Moreb J; Leather H; Braylan R; Rowe TC; Fieniewicz KJ; Wingard JR
Leuk Lymphoma; 2002 May; 43(5):989-99. PubMed ID: 12148910
[TBL] [Abstract][Full Text] [Related]
5. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
6. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
7. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Saraiya B; Gounder M; Dutta J; Saleem A; Collazo C; Zimmerman L; Nazar A; Gharibo M; Schaar D; Lin Y; Shih W; Aisner J; Strair RK; Rubin EH
Anticancer Drugs; 2008 Apr; 19(4):411-20. PubMed ID: 18454051
[TBL] [Abstract][Full Text] [Related]
8. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR
Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811
[TBL] [Abstract][Full Text] [Related]
11. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
12. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
13. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
Perkins JB; Goldstein SC; Dawson JL; Kim J; Field TL; Partyka JS; Fields KK; Maddox BL; Simonelli CE; Neuger AM; Lush RM; Sullivan DM
Clin Cancer Res; 2011 Dec; 17(24):7743-53. PubMed ID: 22028494
[TBL] [Abstract][Full Text] [Related]
14. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
Levitt NC; Propper DJ; Madhusudan S; Braybrooke JP; Echeta C; Te Poele R; Davies SL; Flanagan E; Hickson ID; Joel S; Ganesan TS
Br J Cancer; 2005 Jul; 93(1):60-9. PubMed ID: 15956976
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
Crump M; Couban S; Meyer R; Rudinskas L; Zanke B; Gluck S; Maksymiuk A; Hoskins P; Matthews S; Eisenhauer E
Leuk Lymphoma; 2002 Aug; 43(8):1581-7. PubMed ID: 12400600
[TBL] [Abstract][Full Text] [Related]
17. Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Dowlati A; Levitan N; Gordon NH; Hoppel CL; Gosky DM; Remick SC; Ingalls ST; Berger SJ; Berger NA
Cancer Chemother Pharmacol; 2001; 47(2):141-8. PubMed ID: 11269740
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
[TBL] [Abstract][Full Text] [Related]
19. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
20. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]